Schizophrenia Research
Volume 88, Issue 1 , Pages 5-25, December 2006

Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review

  • Brendan P. Murphy

      Affiliations

    • ORYGEN Youth Health, Melbourne, Victoria, Australia
    • Department of Psychiatry, University of Melbourne, Victoria, Australia
  • ,
  • Young-Chul Chung

      Affiliations

    • Department of Psychiatry, Chonbuk National University Medical School, San 2-20 Geumam-dong, Deokjin-gu, 561-756, Jeonju, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 63 250 2185; fax: +82 63 275 3157.
  • ,
  • Tae-Won Park

      Affiliations

    • Department of Psychiatry, Chonbuk National University Medical School, San 2-20 Geumam-dong, Deokjin-gu, 561-756, Jeonju, South Korea
  • ,
  • Patrick D. McGorry

      Affiliations

    • ORYGEN Youth Health, Melbourne, Victoria, Australia
    • Department of Psychiatry, University of Melbourne, Victoria, Australia

Received 10 January 2006; received in revised form 5 July 2006; accepted 5 July 2006. published online 24 August 2006.

Abstract 

Background

Optimal treatment of primary negative symptoms is important because their presence is associated with poor outcome.

Aims

To systematically review all studies dealing with the efficacy of pharmacological agents on primary negative symptoms.

Method

A comprehensive search of the relevant literature was undertaken using electronic database, reference lists and personal contact.

Results

There is a lack of standardized research designs. Amisulpride is the most extensively studied drug with respect to efficacy against primary negative symptoms. At low doses it demonstrates a consistent, modest effect compared to placebo, though not to conventional antipsychotics and has yet to be tested against other atypicals. Evidence from multiple studies that used simple statistical analyses and inclusion criteria for patients with primary negative symptoms does not support a direct effect for clozapine. Path-analysis studies support the direct effects of risperidone, olanzapine, sertindole and aripiprazole, however, different statistical analyses of the same risperidone study produced conflicting results and the direct effects of olanzapine were not confirmed in selected patients with primary negative symptoms. There are no studies supporting the use of ziprasidone or quetiapine. The effects of typical antipsychotics on primary negative symptoms are inconclusive and likely to depend on drug dosages. Selective serotonin reuptake inhibitors (SSRIs), mirtazepine and NMDA agonists show early promise but require further study. Novel agents such as selegiline, naltrexone, dehydroepiandrosterone, galantamine, Ginkgo, nitric oxide, l-deprenyl and pergolide show positive effects on general negative symptoms but remain untested against primary negative symptoms.

Conclusions

Further studies using standardized selective inclusion criteria and controlling for chronicity are needed. Research guidelines are discussed.

Keywords: Primary, Negative, Schizophrenia, Atypical, Typical, Antidepressant, Psychological

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-9964(06)00311-2

doi:10.1016/j.schres.2006.07.002

Schizophrenia Research
Volume 88, Issue 1 , Pages 5-25, December 2006